Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication

I. J. Choi, H. C. Jung, K. W. Choi, Ji Hoon Kim, D. S. Ahn, U. S. Yang, J. S. Rew, S. I. Lee, J. C. Rhee, I. S. Chung, J. M. Chung, W. S. Hong

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Proton pump inhibitor-based triple therapies are recommended as the first-line treatment for Helicobacter pylori eradication. Aim: To evaluate the efficacies of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy in a metronidazole resistance prevalent area and to compare the efficacies with standard triple therapy. Methods: In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg). The three groups received each regimen twice daily for 7 days. Upper gastrointestinal endoscopy was performed before and 4 weeks after treatment. H. pylori status was determined by rapid urease test and 13C urea breath test. Results: The eradication rates in the OAC250, OAC5O0 and OTC groups were 76.2%, 65.7% and 64.8% (95% confidence interval: 67.9-84.4%, 56.7-74.8% and 55.7-73.9%), respectively, by intention-to-treat analysis (P = 0.149) and 92.8%, 87.2% and 84.1% (95% confidence interval: 84.4-97.3%, 77.9-93.8% and 73.9-91.2%), respectively, by per protocol analysis (P = 0.088). All regimens were well tolerated and compliance was excellent. Conclusions: Both low-dose clarithromycin triple therapy and tinidazole-containing triple therapy are effective and safe regimens for H. pylori eradication.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number1
DOIs
Publication statusPublished - 2002 Feb 14

Fingerprint

Tinidazole
Clarithromycin
Helicobacter pylori
Omeprazole
Amoxicillin
Therapeutics
Confidence Intervals
Intention to Treat Analysis
Breath Tests
Gastrointestinal Endoscopy
Urease
Proton Pump Inhibitors
Dyspepsia
Metronidazole
Duodenal Ulcer
Compliance
Multicenter Studies
Urea
Prospective Studies

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. / Choi, I. J.; Jung, H. C.; Choi, K. W.; Kim, Ji Hoon; Ahn, D. S.; Yang, U. S.; Rew, J. S.; Lee, S. I.; Rhee, J. C.; Chung, I. S.; Chung, J. M.; Hong, W. S.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 1, 14.02.2002, p. 145-151.

Research output: Contribution to journalArticle

Choi, IJ, Jung, HC, Choi, KW, Kim, JH, Ahn, DS, Yang, US, Rew, JS, Lee, SI, Rhee, JC, Chung, IS, Chung, JM & Hong, WS 2002, 'Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication', Alimentary Pharmacology and Therapeutics, vol. 16, no. 1, pp. 145-151. https://doi.org/10.1046/j.1365-2036.2002.01130.x
Choi, I. J. ; Jung, H. C. ; Choi, K. W. ; Kim, Ji Hoon ; Ahn, D. S. ; Yang, U. S. ; Rew, J. S. ; Lee, S. I. ; Rhee, J. C. ; Chung, I. S. ; Chung, J. M. ; Hong, W. S. / Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. In: Alimentary Pharmacology and Therapeutics. 2002 ; Vol. 16, No. 1. pp. 145-151.
@article{9227a52e9eb647d1b324590d961ddcb8,
title = "Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication",
abstract = "Background: Proton pump inhibitor-based triple therapies are recommended as the first-line treatment for Helicobacter pylori eradication. Aim: To evaluate the efficacies of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy in a metronidazole resistance prevalent area and to compare the efficacies with standard triple therapy. Methods: In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg). The three groups received each regimen twice daily for 7 days. Upper gastrointestinal endoscopy was performed before and 4 weeks after treatment. H. pylori status was determined by rapid urease test and 13C urea breath test. Results: The eradication rates in the OAC250, OAC5O0 and OTC groups were 76.2{\%}, 65.7{\%} and 64.8{\%} (95{\%} confidence interval: 67.9-84.4{\%}, 56.7-74.8{\%} and 55.7-73.9{\%}), respectively, by intention-to-treat analysis (P = 0.149) and 92.8{\%}, 87.2{\%} and 84.1{\%} (95{\%} confidence interval: 84.4-97.3{\%}, 77.9-93.8{\%} and 73.9-91.2{\%}), respectively, by per protocol analysis (P = 0.088). All regimens were well tolerated and compliance was excellent. Conclusions: Both low-dose clarithromycin triple therapy and tinidazole-containing triple therapy are effective and safe regimens for H. pylori eradication.",
author = "Choi, {I. J.} and Jung, {H. C.} and Choi, {K. W.} and Kim, {Ji Hoon} and Ahn, {D. S.} and Yang, {U. S.} and Rew, {J. S.} and Lee, {S. I.} and Rhee, {J. C.} and Chung, {I. S.} and Chung, {J. M.} and Hong, {W. S.}",
year = "2002",
month = "2",
day = "14",
doi = "10.1046/j.1365-2036.2002.01130.x",
language = "English",
volume = "16",
pages = "145--151",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication

AU - Choi, I. J.

AU - Jung, H. C.

AU - Choi, K. W.

AU - Kim, Ji Hoon

AU - Ahn, D. S.

AU - Yang, U. S.

AU - Rew, J. S.

AU - Lee, S. I.

AU - Rhee, J. C.

AU - Chung, I. S.

AU - Chung, J. M.

AU - Hong, W. S.

PY - 2002/2/14

Y1 - 2002/2/14

N2 - Background: Proton pump inhibitor-based triple therapies are recommended as the first-line treatment for Helicobacter pylori eradication. Aim: To evaluate the efficacies of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy in a metronidazole resistance prevalent area and to compare the efficacies with standard triple therapy. Methods: In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg). The three groups received each regimen twice daily for 7 days. Upper gastrointestinal endoscopy was performed before and 4 weeks after treatment. H. pylori status was determined by rapid urease test and 13C urea breath test. Results: The eradication rates in the OAC250, OAC5O0 and OTC groups were 76.2%, 65.7% and 64.8% (95% confidence interval: 67.9-84.4%, 56.7-74.8% and 55.7-73.9%), respectively, by intention-to-treat analysis (P = 0.149) and 92.8%, 87.2% and 84.1% (95% confidence interval: 84.4-97.3%, 77.9-93.8% and 73.9-91.2%), respectively, by per protocol analysis (P = 0.088). All regimens were well tolerated and compliance was excellent. Conclusions: Both low-dose clarithromycin triple therapy and tinidazole-containing triple therapy are effective and safe regimens for H. pylori eradication.

AB - Background: Proton pump inhibitor-based triple therapies are recommended as the first-line treatment for Helicobacter pylori eradication. Aim: To evaluate the efficacies of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy in a metronidazole resistance prevalent area and to compare the efficacies with standard triple therapy. Methods: In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg). The three groups received each regimen twice daily for 7 days. Upper gastrointestinal endoscopy was performed before and 4 weeks after treatment. H. pylori status was determined by rapid urease test and 13C urea breath test. Results: The eradication rates in the OAC250, OAC5O0 and OTC groups were 76.2%, 65.7% and 64.8% (95% confidence interval: 67.9-84.4%, 56.7-74.8% and 55.7-73.9%), respectively, by intention-to-treat analysis (P = 0.149) and 92.8%, 87.2% and 84.1% (95% confidence interval: 84.4-97.3%, 77.9-93.8% and 73.9-91.2%), respectively, by per protocol analysis (P = 0.088). All regimens were well tolerated and compliance was excellent. Conclusions: Both low-dose clarithromycin triple therapy and tinidazole-containing triple therapy are effective and safe regimens for H. pylori eradication.

UR - http://www.scopus.com/inward/record.url?scp=0036164002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036164002&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01130.x

DO - 10.1046/j.1365-2036.2002.01130.x

M3 - Article

VL - 16

SP - 145

EP - 151

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -